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Introduction
We believe there is an urgent need for
longitudinal cohorts based in sub-Saharan
Africa (SSA). This conclusion is drawn
from the fact that non-communicable
diseases (NCDs) cause a large and growing
disease burden (please see Box 1) [1–6].
In the past, public health in SSA has
focused on communicable diseases. The
advent of HIV/AIDS reinforced this
image of infections as SSA’s major health
burden. However, NCDs, including car-
diovascular diseases, mental illnesses, trau-
ma, cancer, and diabetes, are now major
sources of morbidity and mortality and are
projected to overtake infectious diseases by
2030 [7,8]. We argue that SSA lacks
adequate resources to respond to this
problem.
Prospective cohort studies can be used
to study multiple complex diseases and risk
factors simultaneously over an individual’s
lifetime. Such studies have proved crucial
in understanding the etiology, course, and
outcome of NCDs in other populations
and have informed the design of preven-
tion programs. In addition, cohort studies
provide an incomparable resource for the
training of public health researchers.
Because the payoff from cohort studies
continues—and often grows—over time,
they are a long-term investment in public
health.
In order to highlight the potential
impact of cohort studies in SSA, we
compared published literature on NCDs
from longitudinal studies in high-income
countries to publications from Africa.
Further, we estimated the costs of estab-
lishing cohort studies in SSA and describe
the response needed to correct the dispar-
ities in research investment between SSA
and the world’s more wealthy regions.
What We Have Learned from
Prospective Cohorts in the
Wealthy Countries
In 2001, Pettiti prepared a list of 55
important findings from epidemiological
studies for the Epidemiology Monitor [9].
This list, reproduced and recently revised
by Dr. Pettiti (personal communication, D.
Pettiti) in Table 1, represents only a partial
inventory of epidemiological discoveries
and does not refer exclusively to cohorts
but all epidemiological designs.
Colditz and Winn recently proposed
criteria by which the success of large cohort
studies can be judged [10]. The criteria they
suggest are: (1) discovery, (2) development,
and (3) delivery. Discovery refers to the
ability to explain disease etiology and is
measured by numbers of publications and
the impact factor of the journals in which
they are published. Development refers to
the provision of a basis for developing
prevention and control measures for popu-
lations at risk. Development is measured by
contribution to the determination of factors
causing disease, providing scientific support
for prevention, clinical guidelines and ran-
domized trials, and quantification of the
preventable burden of disease. Delivery
refers to the implementation of findings
from the discovery and development phase
by clinicians, public health practitioners,
policy makers, and the general public.
Delivery is measured by health policies,
industry applications, and public awareness.
Although these criteria were applied to
studies of cancer epidemiology, they are
more broadly applicable. When applied to
the Nurses’ Health Study (NHS), a longitu-
dinal cohort begun in 1976 with 121,700 US
female registered nurses, this one study
contributed importantly according to the
Colditz andWinn’s criteria. Because cohorts
are able to focus on multiple outcomes, they
can demonstrate the full public health
impact of lifestyle factors.
International Disparity in
Investment in NCD Research
International Disparity in
Publications
We attempted to quantify numbers of
publications in the following manner. We
searched the PubMed on-line database [11]
up to November 26, 2009. We included the
Medical Subject Headings (MeSH) ‘‘cohort
studies’’ in combination with ‘‘Africa South
of the Sahara’’ and two NCDs: ‘‘stroke’’ and
‘‘diabetes mellitus.’’ Each condition was
limited to being a major subject matter.
We repeated each search, changing ‘‘Africa
South of the Sahara’’ to ‘‘United States,’’
‘‘China,’’ ‘‘India,’’ and ‘‘Europe.’’ We used
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the PubMed limit function to limit each
search to those articles involving humans,
having an abstract, and written in English.
We counted citations retrieved by these
strategies.
We estimated the number of people with
diabetes and the number at risk for stroke
(those with hypertension) in each area from
the following sources. Total population was
from The WHO’s World Health Statistics
2008 [12]. The prevalence of hypertension
in the US was from the National Center for
Health Statistics [13]. The prevalence of
hypertension in Africa [14–18], Europe
[19], China [20], and India [21] was
estimated from several sources. The preva-
lence of diabetes for all countries and regions
was from the International Diabetes Feder-
ation 2009 Diabetes Atlas [5].
We calculated the number of publications
per million people for each condition in each
geographic region (Figures 1 and 2). Conti-
nental Africa produced a tiny fraction of the
publications from cohort studies per affected
population compared to the US: 0.6% for
stroke and 8% for diabetes.
International Disparity in Adults
Enrolled in Long-Term Cohorts
No central database of numbers of
adults enrolled in long-term cohorts of
NCDs exists. We have relied on our
knowledge of the epidemiology field and
that of our colleagues to estimate the
proportions of populations enrolled. This
method is admittedly crude and we have
assuredly missed many. For instance, large
populations in North America and Europe
are monitored through data linkage to the
health care system and are regularly used
as cohorts. However, we believe that one
brief example can provide a conservative
estimate of the magnitude of the disparity.
In the US there are 18 cohorts and 2.9
million participants that are part of The
Pooling Project [22].
For Africa we included the following
cohorts. The Birth to Twenty Cohort studies
the health of young adults born in 1990 in
Johannesburg-Soweto, South Africa [23].
The Heart of Soweto is a health facility-
based South African study that enrolled
4,162 cardiovascular disease cases in 2006.
The Women’s Health Study of Accra,
Ghana enrolled 1,328 women to study the
prevalence of communicable diseases and
NCDs [24,25]. The total cohort enrollment
from these three sources is 8,763.
Using the populations of the US and
Africa from the WHO’s World Health
Statistics 2008 [12], we found that com-
pared to the US, Africa had 0.1% as many
cohort enrollees. Given that there are
certainly more US enrollees than we have
counted, and unlikely to be large African
cohorts that we have missed, the disparity
is likely to be even larger. Recent calls to
create even more US cohorts to study gene
environment interactions [26,27] would
increase this disparity.
INDEPTH is an organization that eval-
uates population demography in developing
countries, including 12 in SSA [28]. Because
they assess primarily births, deaths, migra-
tion, and not risk factors or longitudinal
data, we have not included them in our
count of SSA cohorts. Although some have
NCD projects, a massive input of resources
would be required to convert them to true
prospective cohorts.
International Disparity in Research
Money Spent
In 2008 the Global Forum for Health
Research published the document ‘‘Mon-
itoring Financial Flows for Health Re-
search 2007’’ [29], the preface of which
reads:
Since [1990] the landscape of health
research for development has changed in
important ways:
N global expenditure on health research has more
than quadrupled to over US$125 billion in
2003;
N there are many more actors engaged in funding
or conducting health research relevant to the
needs of developing countries;
N but the epidemiology of diseases has shifted
substantially, so that many developing coun-
tries are now experiencing high burdens of
non-communicable diseases such as cancer,
diabetes, heart disease, and stroke, as well as
continuing high burdens of infectious diseases
and injuries.
As a result of these changes, the total global
expenditure applied to research relevant to
all the health problems of developing
countries cannot be estimated with any
meaningful degree of accuracy.
Yet Chapter 5 of this same document,
called ‘‘Using Bibliometrics to Inform
Cancer Research and Spending,’’ used
publication numbers and estimated cost
per paper to estimate total world cancer
research expenditures. This provides as-
surance that the disparity in publications
calculated previously can provide insight
into the disparity in money spent.
International Disparity in Scientific
Person-Power
Economic development is intrinsically
linked to science and technology produced
by academic, technical, and professional
institutions [30]. Currently, many SSA
countries have small scientist pools be-
cause of limited research funding and few
viable career paths. Lasting, indigenous
capacity building in public health requires
the development of scientific training and
capabilities for research.
What Africa Can Teach Us
There is no reason to doubt that smoking,
obesity, high salt intake, sedentary lifestyle
and pollution will have adverse health effects
in Africa as in other places.
Why then do we need to do cohort
studies in Africa? We suggest the following
Box 1. Selected Statistics on Non-Communicable Disease
Burden in Sub-Saharan Africa
Non-communicable disease (NCD) burden
N Over 80% of deaths from non-communicable diseases worldwide are estimated
to occur in low- and middle-income countries [2].
Cardiac diseases
N The World Health Organization projects that the number of deaths from
ischaemic heart disease in the African region will double by 2030 [3].
Stroke
N In 2004 stroke was estimated to cause 3% of all deaths in Africa and 52% of
vascular deaths [4].
Diabetes Mellitus
N The prevalence of diabetes mellitus in Africa is predicted to increase by 80% in
20 y [5].
Cancer
N One in five deaths from NCDs in adults over 45 y in Africa is estimated to be
caused by cancer [6].
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Table 1. Epidemiology triumphs.
Category Disease Risk Factor Direction
Alcohol Esophageal cancer Alcohol interaction with smoking IR
Viruses Liver cancer Hepatitis B virus IR
Burkitt’s lymphoma Epstein Barr virus IR
Kaposi’s sarcoma Herpes simplex virus type 8 IR
Cervical cancer Human papilloma virus IR
Nasopharyngeal cancer Epstein Barr virus IR
Yellow fever Transmitted by mosquitoes IR
Creutzfeldt-Jacob disease Prions (interaction with genotype) IR
Bacteria Cholera ‘‘Something in water’’ (vibrio cholera) IR
Peptic ulcer Helicobacter pylori IR
Puerperal fever ‘‘Something on doctors’ hands’’ (group B Streptococcus) IR
Nutrition Pellagra ‘‘Something in food’’ (niacin) P
Neural tube defects Folic acid, folate P
Oral clefts Folic acid, folate P
Occupation Lung cancer Asbestos (interaction with smoking) IR
Lung cancer ‘‘Something in uranium mines’’ (interaction with smoking) IR
Bladder cancer Aniline dye IR
Mesothelioma Asbestos IR
Angiosarcoma Vinyl chloride IR
Nasal cancer Nickel IR
Male infertility Dibromochlorpropane (DBCP soil fumigant) IR
Scrotal cancer Chimneysweep IR
Environment Cancer Arsenic IR
Chloracne Dioxin IR
Polychlorinated biphenyls Hyperpigmentation at birth IR
Chlordecone (Kepone pesticide) Tremor IR
Methyl mercury exposure from eating
fish due to water contamination during
manufacture of plastics
Severe neurologic disease/cerebral palsy
with intrauterine exposure. Sensory disorders in adults
IR
Dental caries Fluoride IR
Drugs & devices Myocardial infarction Aspirin P
Microagnathia Iso-retinone during pregnancy IR
Pelvic inflammatory disease Dalkon shield IUD IR
Septic abortion Dalkon shield IUD IR
Hormones Clear cell adenocarcinoma of the vagina Diethylstibestrol IR
Venous thromboembolism Oral contraceptives IR
Venous thromboembolism Post menopausal estrogen IR
Ovarian cancer Oral contraceptives P
Endometrial cancer Oral contraceptives P
Endometrial cancer Post menopausal estrogen IR
Iron deficiency anemia Oral contraceptives P
Benign breast disease Oral contraceptives P
Myocardial infarction Oral contraceptives (interaction with smoking) IR
Ischemic stroke Oral contraceptives (interaction with hypertension; modified by dose) IR
Genetics Breast cancer BRCA1, BRCA2 mutations IR
Ovarian cancer BRCA2 mutations IR
Colon cancer APC1 mutations IR
Miscellaneous Toxic shock syndrome Super absorbent tampons IR
Sudden infant death Prone sleep position IR
Reye’s syndrome Aspirin (interaction with infection) IR
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reasons: to study population-specific dis-
ease burden; genetic heterogeneity; un-
paralleled geographic, social and cultural
diversity; practices and secular trends that
may be unique risk factors; and to
stimulate political will for health promot-
ing change.
Scientific findings from North America
and Europe may not be applicable to
other regions. Longitudinal studies track
changes in risk factors over time and
provide health planners with information
on disease burden. One example would be
hypertension prevalence. This has been
considered a problem of more wealthy,
sedentary and obese urban but not rural
African populations [15]. Yet blood pres-
sure measurements from cross-sectional
studies in several rural African locations
have found a hypertension prevalence of
11%–25%, similar to that in the cities and
in high income countries [15,16]. A cross-
sectional study of 1,500 rural villagers over
age 15 in three nations (Tanzania, Ma-
lawi, and Rwanda) found 23% had
hypertension that was independent of
obesity (mean body mass index was
21 kg/m2) and associated with diet [31].
Others have confirmed these findings
[17,18]. The assessment that hypertension
is mainly a problem of cities is therefore
wrong. Global dietary changes will affect
the trajectory of hypertension prevalence
Category Disease Risk Factor Direction
Smoking Lung cancer Smoking IR
Coronary disease Smoking IR
Hemorrhagic stroke Smoking IR
Ischemic stroke Smoking IR
Abdominal aortic aneurysm Smoking IR
Peripheral vascular disease Smoking IR
Parkinson’s disease Smoking P
Ulcerative colitis Smoking P
Laryngeal cancer Smoking IR
Intrauterine growth retardation Smoking during pregnancy IR
Toxemia/preeclampsia Smoking during pregnancy P
From Petitti D, Epidemiology Monitor, July 30, 2001, and revised May 2009, http://www.epimonitor.net/EpiMonday/Triumph62501.htm, used with permission. IR,
increased risk; P, protective.
doi:10.1371/journal.pmed.1000244.t001
Table 1. Cont.
Figure 1. Ratio of numbers of publications from cohort studies by condition (graph). Ratio of numbers of publications from cohort studies by
condition (stroke, diabetes mellitus) per million people with the disease (diabetes) or at risk of the disease (stroke) in Africa, Europe, China, India, and the US.
doi:10.1371/journal.pmed.1000244.g001
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in the future, and cohorts will give
information on this trajectory that the
cross-sectional studies cannot.
Diet is another location-specific cultur-
al practice. Although we know from
studies in high income countries that
consumption of whole grain based on
mostly wheat and rice is associated with
lower risk of diabetes [32], this may not
be applicable in East Africa where the
staple is corn. We need to research local
foods that confer protection to formulate
interventions.
History is also location specific. With
the exception of studies of starved Euro-
peans during World War II [33], studies of
the West’s obesity epidemic have all been
among populations with a lifetime of more
than adequate energy intake. In Africa,
under-nutrition remains common [34] yet
coexists with the global obesity epidemic
[16,35,36]. Evidence from high income
countries shows that intrauterine growth
retardation predisposes to increased risk of
cardiovascular and metabolic diseases
[37–41]. The effects of the collision of
these two secular trends in Africa (recent
under-nutrition and rapid introduction of
obesity-enhancing lifestyle factors) cannot
be fully anticipated.
The high prevalence of infectious dis-
eases such as HIV in SSA along with
NCDs is another location-specific oppor-
tunity. Inflammation common to infec-
tions is increasingly known to be impor-
tant for cardiovascular, metabolic, and
neoplastic disease [42–44]. SSA presents
the opportunity to better understand this
pathophysiology.
Adding to the complexity of locale-
specific behavior and history is genetic
diversity. Humans first evolved in East
Africa, and thus African genetic diversity is
greater than elsewhere [45]. Studying the
interaction between environmental factors
and genes elucidates disease mechanisms.
If one multiplies the extended range of
cultural practices and historical circum-
stances by the genetic diversity found in
Africa, the opportunities for scientific
discovery become enormous (S. Dalal,
M.D. Holmes, R. Ramesar. Advancing
public health genomics in Africa through
prospective cohort studies. Journal of Epi-
demiology and Community Health [In press]).
Even if smoking and intake of salt and
refined grains has been shown detrimental
in higher income populations, political will
for change may be greater among policy
makers, clinicians, and the public if shown
in their own population.
Although cohort methodology devel-
oped in North America and Europe, high
income countries may also gain from
knowledge derived from African studies.
For example, the obesity epidemic in the
West is well developed; we have yet to
apply our knowledge to interventions
having substantial impact [46].
Estimated Cost of African
Cohorts
We propose cohort studies of 50,000 to
100,000 people in three or four countries
covering west, east, and southern Africa.
The higher number would increase en-
rollment of Africans to 532 per million,
still only 5% compared to the US.
These studies will include the collection
and storage of biological specimens, re-
peated exposure measurements, and on-
going ascertainment of disease among
participants. Disease ascertainment poses
particular challenges in countries without
strong health systems. It will be important
to choose strategies that accommodate
local circumstances.
We propose to include populations that
are urban, rural, and include men,
women, and children. We have four
overarching goals: (1) to measure disease
burden; (2) to study the etiology of NCDs,
the distribution of risk factors, and
attributable risks; (3) to provide short-
term results by nesting randomized inter-
vention trials within the cohorts; and (4)
to stimulate academic development and
collaboration.
Figure 2. Ratio of numbers of publications from cohort studies by condition (table). Ratio of numbers of publications from cohort studies
by condition (stroke, diabetes mellitus) per million people with the disease (diabetes) or at risk of the disease (stroke) in Africa, Europe, China, India,
and the US, and ratio of these publications with US as the reference group.
doi:10.1371/journal.pmed.1000244.g002
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Ideal study sites would be those where
African colleagues have some history of
cooperation with the population. Sites
with established assessments or interven-
tions may offer cost savings. However,
such sites are not likely to easily accom-
modate the additional proposed layers of
complexity, including multiple research
designs, multinational collaborators, and
managing new enrollees with ongoing
study participants separately.
Cohort Costs
We estimated costs for establishing
cohorts in two ways. The first was by
comparison to the mail-based NHS costs
for April 1, 2005 to March 31, 2006 in
Table S1 (personal communication, S.
Hankinson). Personnel costs are lower in
Africa than in the US. We used the Source
of International Wage Comparisons com-
piled by the financial firm UBS to
calculate wage differences (Table S2)
[47]. Using this method, we estimated
the cost of an African cohort of 100,000
participants to be $1.2 million per year, or
$12/person/year (Table S3).
Costs could be higher without a reliable
mail system; thus we estimated African
cohort costs a second way. We applied
the costs of a cohort of 775 patients
followed for HIV medication compliance
in rural Uganda (personal communication,
D. Bangsberg). One year costs were
$494,256, or $638/person/year.
Randomized Trial Costs
We used information from a random-
ized controlled trial (RCT) of single versus
multiple doses of multivitamins in addition
to ART for women with HIV in Tanzania
to estimate the cost of a RCT (personal
communication, W. Fawzi). The cost was
$4 million for 5 y for 3,000 people.
However, this included multiple laborato-
ry measurements because participants
were ill. Assuming half the cost for an
intervention in well people, we estimate
RCT costs to be as low as $135/person/
year. We applied a range of $135–$270/
person/year to our estimates.
The prevalence of hypertension in
Africa is similar to the US [15,16]. The
Dietary Approaches to Stop Hypertension
(DASH) trial significantly lowered blood
pressure among 459 hypertensive Ameri-
cans [48]. An illustrative intervention
would be to do an ‘‘African DASH’’ trial
substituting culturally appropriate foods to
lower blood pressure among 500 Africans
lasting 2 y. We propose doing a total of
five similar interventions addressing dis-
eases of the epidemiologic transition over
10 y. The costs for 500 people
62 y6($135–$270)65 similar type inter-
ventions = $675,000 to $1.35 million.
Training Costs
We assumed the costs of educating
African scholars using tuition and living
expenses at Harvard School of Public
Health [49,50]. We propose other concom-
itant models for training including lecturers
in residence at African universities, short
courses, and distance learning. We assumed
a range of costs depending on the degree
program (master’s or doctorate) and wheth-
er the student was single or had a family.
The cost per student given in Table S4
ranges from $110,000 to $269,000.
Total Cost Scenarios
Table S5 summarizes the assumptions
of the range of costs explained in this
section. We assumed cohorts would extend
at least 10 y; in a recent review successful
large cohorts experienced exponential
publication growth after 10 y [10]. We
then applied high and low costs for the
cohort, interventions, and for training, and
combinations thereof in Table 2. The low
estimate including interventions and train-
ing is $23.7 million for a cohort of 50,000
people in three countries each. The high
estimate is for $2.56 billion for a cohort of
100,000 people in four countries each.
Comparisons are useful. PEPFAR cost
$18.8 billion for 5 y only for HIV/AIDS
[51]. The Bill and Melinda Gates Foun-
dation will spend $3.9 billion in 2009 on
various causes including global health
[52]. Harvard University’s fundraising for
fiscal year 2006 was $600 million [53].
The UK Biobank, a cohort of 500,000
people with a baseline assessment only and
8 y of follow-up linked to a national health
record, will cost $104 million [54]. The
similar Swedish LifeGene cohort of
500,000 people and with baseline assess-
ment and 8 y of follow-up will cost $112
million (personal communication H.-O.
Adami). Translated into costs per person
per year, the UK Biobank is $26 and
LifeGene is $28. The high and low
estimates of the African initiative gives a
range from $14 to $644/person/year for
the added value beyond the European
cohorts of repeated exposure measure-
ments, embedded interventions, and aca-
demic capacity building. Other scenarios
of different size and intensity could be
entertained. For instance, a large company
that already conducts periodic health
examinations of employees might be
economically converted to a cohort. Also,
funding need not necessarily come from a
single source. However, some costs for an
African cohort will be higher than a
similar cohort in Europe or North Amer-
ica. A generous budget for travel will be
needed to allow newly trained personnel to
return to the host institution for further
Table 2. African Cohort Initiative named PaCT (Partnership for Cohort Research and Training) – Estimation of range of costs for
two scenarios.
Four Countries Three Countries
(N=100,000/Country) (N=50,000/Country)
High Low High Low
Cohort 2,000,000,000 48,000,000 750,000,000 18,000,000
Intervention 1,350,000 675,000 1,350,000 675,000
Training 9,296,000 6,720,000 6,972,000 5,040,000
Totals
Cohort+Interventions 2,001,350,000 48,675,000 751,350,000 18,675,000
Cohort+Training 2,009,296,000 54,720,000 756,972,000 23,040,000
Cohort+Interventions+Training 2,010,646,000 55,395,000 758,322,000 23,715,000
doi:10.1371/journal.pmed.1000244.t002
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contact and exchange of ideas, but also to
enable experienced researchers to visit the
sites frequently.
Sustainability
Yach defined the following obstacles
impeding attention to NCDs in developing
countries: policy makers lack evidence of
disease burden, beliefs that NCDs affect only
the wealthy and elderly, that they arise only
from freely acquired risks, and that their
control is expensive, ineffective, and a lower
priority than infectious diseases [7].
These obstacles will need to be addressed
if cohort studies of NCDs are to be
sustainable. Health systems will have to be
strengthened to absorb the disease burden
uncovered by research. Training programs
in public health disciplines are also neces-
sary for long-term career development for
the next generation of researchers.
We believe that starting large cohort
studies in Africa is a 21st century design to
serve public health in Africa. It combines
surveillance, epidemiology, and clinical tri-
als, and could yield information relevant to
the NCD epidemic in wealthy countries.
The funding for such an initiative will
require political leadership, a long vision of
the possibilities, and patience in awaiting
results. We hope that the growing burden of
NCDs and the unfulfilled need for research
and action will spur funders of global health
to include NCDs in Africa in their agenda.
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